No change in cortical muscarinic M2, M3 receptors or [35S]GTPγS binding in schizophrenia
- 1 February 2006
- journal article
- Published by Elsevier BV in Life Sciences
- Vol. 78 (11), 1231-1237
- https://doi.org/10.1016/j.lfs.2005.06.038
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Muscarinic receptors in schizophrenia.Current Molecular Medicine, 2003
- Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophreniaMolecular Psychiatry, 2002
- Muscarinic receptors as a target for drugs treating schizophrenia.Current Drug Targets-CNS & Neurological Disorders, 2002
- Low Muscarinic Receptor Binding in Prefrontal Cortex From Subjects With Schizophrenia: A Study of Brodmann’s Areas 8, 9, 10, and 46 and the Effects of Neuroleptic Drug TreatmentAmerican Journal of Psychiatry, 2001
- Elucidating the role of muscarinic receptors in psychosisLife Sciences, 2001
- Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formationBiological Psychiatry, 2000
- Characterization of receptor-mediated [35S]GTPγS binding to cortical membranes from postmortem human brainEuropean Journal of Pharmacology, 2000
- Pharmacologic strategies for augmenting cognitive performance in schizophreniaBiological Psychiatry, 1999
- Differential Regulation of Molecular Subtypes of Muscarinic Receptors in Alzheimer's DiseaseJournal of Neurochemistry, 1995
- Heterogeneous binding of [3H]4-DAMP to muscarinic cholinergic sites in the rat brain: Evidence from membrane binding and autoradiographic studiesSynapse, 1991